Strategic Alliance SomaLogic has become part of Illumina, creating a combined offering that links proteomics with genomics. This opens sales opportunities to cross-sell integrated proteomics and genomics insights to biopharma, contract research organizations, and academic customers seeking scalable, high-plex data.

High Plex Advantage The SomaScan platform offers ultra high-plex proteomics, including 11,000 measurements in recent launches. This capability can be positioned to enterprises needing broad biomarker panels, longitudinal studies, and large-cohort analyses, appealing to pharmaceutical R&D and clinical research stakeholders.

Strategic Partnerships Recent collaborations with global entities (DNA Link, M42) and ongoing Novo Nordisk engagement indicate a pattern of partnerships to expand adoption and grant-based research funding. Target potential partners in academia, CROs, and pharma to co-create proteomics-enabled programs.

Global Expansion Post-merger access to Illumina’s global reach suggests geographic expansion opportunities. Prioritize outreach in regions where Illumina and SomaLogic have footprint gaps, offering joint data-generation programs and regional prototyping grants to accelerate customer onboarding.

Commercial Readiness SomaLogic maintains a sizable funding base and mid-market revenue profile, with scalable platforms and a clear growth trajectory. Position as the backbone for customers seeking robust, scalable proteomics data with enterprise-grade integrations (Salesforce, HubSpot, Microsoft 365) to support sales workflows and customer success onboarding.